Literatur-verzeichnis

• Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J, Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 2016; 137 (2): 444-451
• Horn A, Zeuner H, Wolf H, Schnitker J, Wüstenberg E. Health-Related Quality of Life During Routine Treatment with the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-Interventional Observational Study. Clin Drug Investig 2016, DOI 10.1007/s40261-016-0388-9
• Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljørring C, Riis B, de Blay F. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma – A Randomized Clinical Trial. JAMA. 2016; 315 (16): 1715-1725.
• Reiber R, Keller M, Keller W, Wolf H, Schnitker J, Wüstenberg E. Tolerability of the SQ‑standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non‑interventional observational study. Clin Transl Allergy 2016;6:9

• Durham SR, Nelson HS, Nolte H, Bernstein DI, Creticos PS, Li Z, Andersen JS, Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. Allergy 2014; 69 (5): 617-623
• Kleine-Tebbe J, Walmar M, Bitsch-Jensen K, Decot E, Pfaar O, de Rojas DH, Rodriguez F, Negative clinical results from a randomised, double-blind, placebocontrolled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose-dependent immunological response. Clin Drug Investig 2014; 34: 577-586
• Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljørring C, Canonica GW, Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014 Sep; 134 (3): 568-575

• Armentia A, Carballada F, Carretero P, de Paz S, Lobera T, Marcos C, Martínez JC, Rodríguez I, Soto T, Venturini M, de la Torre F, Postmarketing study for assessment of tolerability of a grass allergen immunotherapy tablet (GRAZAX) in patients with rhinitis or rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2012; 22 (7): 485-490
• Durham SR, Emminger W, Kapp A, de Monchy JGR, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R, SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129: 717-725
• Lou W, Wang C, Wang Y, Han D, Zhang L, Enhancement of the Frequency and Function of IL-10-Secreting Type I T Regulatory Cells after 1 Year of Cluster Allergen-Specific Immunotherapy. Int Arch Allergy Immunol 2012; 159: 391-398
• Möbs C, Ipsen H, Mayer L, Slotosch C, Petersen A, Würtzen PA, Hertl M, Pfützner W, Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012; 130: 1108-1116
• Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E, Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 2012; 67 (5): 630-637
• Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E, Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial. Clin Ther 2012; 34: 2072-2081
• Shamji MH, Ljørring C, Francis JN, A Calderon M, Larché M, Kimber I, Frew AJ, Ipsen H, Lund K, Würtzen PA, Durham SR, Functional rather than immunoreactive levels of IgG(4) correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012 Feb; 67 (2): 217-226
• Wessel F, Chartier A, Meunier J-P, Magnan A, Safety and Tolerability of an SQ-Standardized Grass Allergy Immunotherapy Tablet (GRAZAX) in a Real-Life Setting for Three Consecutive Seasons – The GRAAL Trial. Clin Drug Investig 2012 Jul 1; 32 (7): 451-463

• Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JGR, Rak S, Scadding GK, Andesen JS, Riis B, Dahl R, Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125: 131-138 33.
• Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB, Clinical efficacy and immunological mecha nisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010 Jun; 40 (6): 922-932
• Frølund L, Durham SR, Calderon M, Emminger W, Andersen JS, Rask P, Dahl R, Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality
  of life. Allergy 2010 Jun 1; 65 (6): 753-757
• Martínez-Cócera C, Sastre J, Cimarra M, Quirce S, Fernández-Rivas M, Enríquez-Matas A, Rodríguez-Álvarez M, Martín S, Immunotherapy with a phleum pratense allergen extract induces an immune response to a grass-mix allergen extract. J Investig Allergol Clin Immunol 2010; Vol. 20(1): 13-19

• Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Riis B, Grønager PM, Durham SR, Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121: 512-518
• Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, Till SJ, Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008 May; 121 (5): 1120-1125
• Henmar H, Lund G, Lund L, Petersen A, Würtzen PA, Allergenicity, immunogenicity and doserelationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008 Sep; 153 (3): 316-323
• Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirican A, Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec. 2008; 70 (3): 144-150
• Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H, A double-blind placebocontrolled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008 Aug; 38 (8): 1290-1301

• Alessandrini AE, Berra D, Rizzini FL et al., Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Ann Allergy Asthma Immunol 2006; 97 (1): 92-97
• Blumberga G, Groes L, Haugaard L, Dahl R, Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006; 61 (7): 843-848
• Calderon M, Essendrop M, Specific immunotherapy with high dose SQ standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006; Vol. 16 (6): 338-344
• Dahl R, Stender A, Rak S, Specific immunotherapy with SQ standardized grass allegen tablets in asthma tics with rhinoconjunctivitis. Allergy 2006; 61: 185-190
• Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Rivas MF, Ribel M, Durham SR, Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118: 434-440
• Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S, Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-809
• Frew AJ, Powell RJ, Corrigan CJ, Durham SR, Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117 (2): 319-325
• Kleine-Tebbe J, Ribel M, Herold DA, Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006; 61: 181-184
• Malling HJ, Lund L, Ipsen H, Poulsen L, Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006; Vol. 16 (3): 162-168
• Niggemann B, Jacobsen L, Dreborg S et al., Five-year follow-up on the PAT study: specific immunotherapy and long- term prevention of asthma in children. Allergy 2006; 61 (7): 855-859
• Quercia O, Emiliani F, Pecora S, Burastero SE, Stefanini GF, Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: comparison of standardized quality depot versus aqueous extract. Allergy Asthma Proc 2006; 27 (2): 151-158
• Roberts G, Hurley C, Turcanu V, Lack G, Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117 (2): 263-268
• Wang H, Lin X, Hao C et al., A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006; 61 (2): 191-197
• Werfel T, Breuer K, Rueff F et al., Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randmized, dose-response study. Allergy 2006; 61 (2): 202-205
• Winther L, Arnved J, Malling HJ, Nolte H, Mosbech H, Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin Exp Allergy 2006; 36 (3): 254-260

• Arvidsson MB, Lowhagen O, Rak S, Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59 (1): 74-80
• Bolhaar ST, Tiemessen MM, Zuidmeer L, van Leeuwen A, Hoffmann-Sommergruber K, Bruijnzeel-Koomen CA, Taams LS, Knol EF, van Hoffen E, van Ree R, Knulst AC, Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004 May; 34 (5): 761-769
• Bucher X, Pichler WJ, Dahinden CA, Helbling A, Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 2004 Dec; 59 (12): 1272-1276
• Cadario G, Marengo F, Ranghino E et al., Higher frequency of early local side effects with aqueous versus depot immunotherapy for hymenoptera venom allergy. J Investig Allergol Clin Immunol 2004; 14 (2): 127-133
• Crimi N, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C, Lisitano N, Polosa R, A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int 2004 Apr-Jun; 19 (2): 98-108
• Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR, Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004 Mar 1; 172 (5): 3252-3259
• Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B, Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed prepartions. Allergy 2004; 59 (6): 589-595
• Savolainen J, Laaksonen K, Rantio-Lehtimäki A, Terho EO, Increased expression of allergen- induced in vitro interleukin-10 and interleukin-18 mRNA in peripheral blood mononuclear cells of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004 Mar; 34 (3): 413-419
• Van Neerven RJ, Arvidsson M, Ipsen H, Sparholt SH, Rak S, Würtzen PA, A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004 Mar; 34 (3): 420-428
• Wilcock LK, Francis JN, Durham SR, Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004 Sep; 34 (9): 1373-1378

• Arvidsson MB, Lowhagen O, Rak S, Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109 (5): 777-783
• Bødtger U, Poulsen LK, Jacobi HH, Malling HJ, The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebocontrolled study. Allergy 2002; 57 (4): 297-305
• Fernandez-Tavora L, Rico P, Martin S, Clinical experience with specific immunotherapy to horse dander. J Investig Allergol Clin Immunol 2002; 12 (1): 29-33
• Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U, Efficacy of combination treatment with anti-IgE plus specific immunotherapy in poly-sensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002 Feb; 109 (2): 274-280
• Möller C, Dreborg S, Ferdousi HA et al., Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109 (2): 251-256
• Oude Elberink JN, De Monchy JG, Van Der HS, Guyatt GH, Dubois AE, Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110 (1): 174-182
• Sturm G, Kranke B, Rudolph C, Aberer W, Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002; 110 (6): 928-933
• Wolf H et al., The LQC-study: quality of life and compliance with specific immunotherapy against grass and rye allergens after 3 years of treatment. Allergy 2002; 57 (73): 77-78

• Akmanlar N, Altintas DU, Güneser KS, Yilmaz M, Bingöl G, Comparison of conventional and rush immunotherapy with der PI in childhood respiratory allergy. Allergol Immunopathol (Madr) 2000 Jul-Aug; 28 (4): 213-218
• Bergmann KC, Wolf H, Petermann F und die LQC Studiengruppe, Lebensqualität und Compliance von Patienten bei der spezifischen Immuntherapie mit Gräser- und Roggenallergenen (LQC-Studie), Allergo J 2000; 9: 480-488
• Brehler R, Wolf H, Kutting B, Schnitker J, Luger T, Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1231-1235
• Mellerup MT, Hahn GW, Poulsen LK, Malling H, Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30 (10): 1423-1429
• Mosbech H, Muller U, Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. Euro pean Academy of Allergology and Clinical Immunology. Allergy 2000; 55 (11): 1005-1010
• Winther L, Malling HJ, Moseholm L, Mosbech H, Allergen-specific immunotherapy in birch and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Allergy 2000 Sep; 55 (9): 818-826
• Winther L, Malling HJ, Mosbech H, Allergen-specific immunotherapy in birch- and grasspollen- allergic rhinitis. II. Side-effects. Allergy 2000 Sep; 55 (9): 827-835

Movérare R, Rak S, Elfman L, Allergen-specific increase in interleukin (IL)-4 and IL-5 secreton from peripheral blood mononuclear cells during birch-pollen immunotherapy. Allergy 1998 Mar; 53 (3): 275-281

• Dolz I, Martínez-Cócera C, Bartolome JM, Cimarra M, A double-blind, placebocontrolled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996; 51 (7): 489-500
• Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA, Grass pollen immuno therapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996 Jun; 97 (6): 1356-1365
• Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ, Antihistamine premedication in specific cluster immuno therapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996 Jun; 97 (6): 1207-1213

• Haugaard L, Dahl R, Jacobsen L, A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91 (3): 709-722
• Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR, Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutane ous responses. J Clin Invest 1993 Aug; 92 (2): 644-651
• Wyss M, Scheitlin T, Stadler BM, Wuthrich B, Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a propective study over 3 years. Allergy 1993; 48 (2): 81-86

• Durham SR, Varney V, Gaga M, Frew AJ, Jacobson M, Kay AB, Immunotherapy and allergic inflammation. Clin Exp Allergy 1991 Jan; 21 (1): 206-210
• Hedlin G, Graff-Lonnevig V, Heilborn H et al., Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87 (5): 955-964
• Rak S, Björnson A, Håkanson L, Sörenson S, Venge P, The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991 Dec; 88 (6): 878-888
• Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR, Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302 (6771): 265-269

• Bertelsen A, Andersen JB, Christensen J, Ingemann L, Kristensen T, Ostergaard PA, Immunotherapy with dog and cat extracts in children. Allergy 1989; 44 (5): 330-335
• Collet M, Urbanek R, Allergenimmunotherapie mit einem immunchemisch charakterisierten Gräserpollen-Extrakt Änderung der Sensibilisierungsparameter im Verlauf. Klin. Pädiatr 1989; 201: 183-188
• Lilja G, Sundin B, Graff-Lonnevig V et al., Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment. J Allergy Clin Immunol 1989; 83 (1): 37-44
  Svendsen UG et al., The effect of immunotherapy on specific and concomitant mugwort pollen allergy in a double blind study. Allergologie 1989; 12 (9): 17-22

• Hedlin G, Graff-Lonnevig V, Heilborn H et al., Immunotherapy with cat- and dog-dander extracts. II. In vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986; 77 (3): 488-496
• Løwenstein H, Graff-Lonnevig V, Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Sundin B, Immunotherapy with cat- and dog-dander extracts. III. Allergen-specific immunoglobulin responses in a 1-year double-blind placebo study. J Allergy Clin Immunol 1986 Mar; 77 (3): 497-505
• Mosbech H, Malling HJ, Biering I et al., Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986; 41 (2): 95-103
• Sundin B, Lilja G, Graff-Lonnevig V et al., Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986; 77 (3): 478-487
• Valovirta E, Viander M, Koivikko A, Vanto T, Ingeman L, Immunotherapy in allergy to dog. Immunologic and clinical findings of a double-blind study. Ann Allergy 1986; 57 (3): 173-179

Valovirta E, Koivikko A, Vanto T, Viander M, Ingeman L, Immunotherapy in allergy to dog: a double-blind clinical study. Ann Allergy 1984; 53 (1): 85-88

• Osterballe O, Egeskjold EM, Johansen AS, Skov P, Anti-IgG antibodies during immunotherapy with purified grass pollen extracts. Allergy 1982 Apr; 37 (3): 209-216
• Osterballe O, Løwenstein H, Malling HJ, Petersen BN, Weeke B, Is is possible to predict the clinical effect of hyposensitization? Int Arch Allergy Appl Immunol 1982; 68 (3): 286-288
• Osterballe O, Løwenstein H, Norn S, Prahl P, Skov P, Skov PS, Weeke B, Immunotherapy with grass pollen major allergens. Immunological results from a prospective 3-year double blind study. Allergy 1982 Oct; 37 (7): 491-501
• Osterballe O, Immunotherapy with grass pollen major allergens. Allergy 1982; 37 (6): 379-388
• Osterballe O, Nasal and skin sensitivity during immunotherapy with two major allergens 19, 25 and partially purified extract of timothy grass pollen. Allergy 1982 Apr; 37 (3): 169-177
• Osterballe O, Side effects during immunotherapy with purified grass pollen extracts. Allergy 1982 Nov; 37 (8): 553-562